Background: Glucocorticoid treatment is recommended as the first-line treatment of MS relapses, however there is still no clear evidence supporting an optimum therapeutic regime. The high dose (HD) consisted of at least 500 mg/day, but the total dose of intravenous MP administered and the regimen varied among studies. The aim of this study was to assess the improvement following a standard regime of IVMP (1 g/day MP given for 10 days, without tapering) for MS relapses. A second objective was to search baseline predictors of outcome. Method: Consecutive treatments with IVMP for ten days (1 g/day, single dose in 150cc. saline, over 40 min) administered at our Neurology clinic for an episode of acute neurological deterioration in 44 patients (55 relapses) diagnosed with RR MS were recruited retrospectively. Results: Attack severity was mild in three, moderate in 28 and severe in 24 relapses. Significant improvement (? 1.0 EDSS point) occurred in 81 % of attacks at one month. The rate of improvement at ten days was 83.6%, and 85.5% at six months. There was no difference in means of latency to treatment between the patients that responded well to therapy and responded poor, at the first month. However response to therapy was higher at the sixth month in patients with latency to treatment shorter than fifteen days (68.4%, 94.4%). Conclusions: In conclusion the results of our retrospectively designed clinical study support that HD MP, 1 g/day for ten days administered IV can accelerate the recovery from MS relapses. This regimen with proper early timing for starting therapy might determine the optimum benefit. © Universitätsverlag Ulm GmbH 2009.

Yazar Unal A.
Sutlas P.N.
Kuscu D.Y.
Emre U.
Yazar T.
Ankarali H.
Kirbas D.
Yayın Türü Article
Tek Biçim Adres https://hdl.handle.net/20.500.12628/4711
Konu Başlıkları High-dose methylprednisolone
Multiple sclerosis
Relapse
Therapy
Koleksiyonlar Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed | SOBİAD
Scopus İndeksli Yayınlar Koleksiyonu
Dergi Adı Neurology Psychiatry and Brain Research
Dergi Cilt Bilgisi 16
Dergi Sayısı 2
Sayfalar 69 - 74
Yayın Yılı 2009
Yazar
[dc.contributor.author]
Unal A.
Yazar
[dc.contributor.author]
Sutlas P.N.
Yazar
[dc.contributor.author]
Kuscu D.Y.
Yazar
[dc.contributor.author]
Emre U.
Yazar
[dc.contributor.author]
Yazar T.
Yazar
[dc.contributor.author]
Ankarali H.
Yazar
[dc.contributor.author]
Kirbas D.
Yayın Yılı
[dc.date.issued]
2009
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Background: Glucocorticoid treatment is recommended as the first-line treatment of MS relapses, however there is still no clear evidence supporting an optimum therapeutic regime. The high dose (HD) consisted of at least 500 mg/day, but the total dose of intravenous MP administered and the regimen varied among studies. The aim of this study was to assess the improvement following a standard regime of IVMP (1 g/day MP given for 10 days, without tapering) for MS relapses. A second objective was to search baseline predictors of outcome. Method: Consecutive treatments with IVMP for ten days (1 g/day, single dose in 150cc. saline, over 40 min) administered at our Neurology clinic for an episode of acute neurological deterioration in 44 patients (55 relapses) diagnosed with RR MS were recruited retrospectively. Results: Attack severity was mild in three, moderate in 28 and severe in 24 relapses. Significant improvement (? 1.0 EDSS point) occurred in 81 % of attacks at one month. The rate of improvement at ten days was 83.6%, and 85.5% at six months. There was no difference in means of latency to treatment between the patients that responded well to therapy and responded poor, at the first month. However response to therapy was higher at the sixth month in patients with latency to treatment shorter than fifteen days (68.4%, 94.4%). Conclusions: In conclusion the results of our retrospectively designed clinical study support that HD MP, 1 g/day for ten days administered IV can accelerate the recovery from MS relapses. This regimen with proper early timing for starting therapy might determine the optimum benefit. © Universitätsverlag Ulm GmbH 2009.
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
High-dose methylprednisolone
Konu Başlıkları
[dc.subject]
Multiple sclerosis
Konu Başlıkları
[dc.subject]
Relapse
Konu Başlıkları
[dc.subject]
Therapy
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
0941-9500
İlk Sayfa Sayısı
[dc.identifier.startpage]
69
Son Sayfa Sayısı
[dc.identifier.endpage]
74
Dergi Adı
[dc.relation.journal]
Neurology Psychiatry and Brain Research
Dergi Sayısı
[dc.identifier.issue]
2
Dergi Cilt Bilgisi
[dc.identifier.volume]
16
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/4711
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
25
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
09 Şubat 2024 08:57
Google Kontrol
Tıklayınız
relapses treatment administered improvement therapy patients latency regimen regime optimum retrospectively responded between Background attacks point) occurred difference months However starting recovery proper timing determine benefit Universitätsverlag accelerate response higher shorter fifteen Conclusions conclusion results
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms